What is Gero?
Headquartered in Singapore with a strategic presence in San Francisco, Gero operates at the forefront of computational biology. The company utilizes a physics-first AI platform to decode the biology of aging, transforming complex clinical, molecular, and genetic datasets into actionable insights for drug discovery. By combining generative AI for small-molecule design with deep biological modeling, Gero is uniquely positioned to identify novel targets for chronic conditions. Its market position is defined by a dual-track strategy: advancing proprietary programs aimed at the fundamental mechanisms of aging while simultaneously forming high-value partnerships with established pharmaceutical entities to address specific age-related pathologies.
How much funding has Gero raised?
Gero has raised a total of $25.2M across 2 funding rounds:
Series A
$8.2M
Other Financing Round
$17M
Series A (2023): $8.2M with participation from Bulba Ventures and Melnichek Investments
Other Financing Round (2026): $17M led by Melnichek Investments
Key Investors in Gero
Melnichek Investments
Melnichek Investments is a venture firm focused on supporting innovative machine learning and biotech startups, leveraging capital from successful tech acquisitions to empower visionary founders.
Bulba Ventures
Bulba Ventures is a strategic investment firm that provides early-stage and growth capital to technology-driven companies, with a particular interest in AI and healthcare innovation.
What's next for Gero?
With this major enterprise-level funding, Gero is poised to transition from a research-heavy development phase into a more aggressive commercial and clinical scaling stage. The capital will likely be deployed to expand the company's computational infrastructure and enhance its ProtoBind-Diff generative AI capabilities, which are critical for rapid small-molecule design. Furthermore, the firm is expected to deepen its collaborative efforts with global pharmaceutical partners, leveraging its AI-enabled target discovery platform to shorten the drug development lifecycle. As Gero continues to bridge the gap between physics-based modeling and clinical application, the focus will remain on validating its therapeutic candidates in human health contexts, ultimately aiming to redefine the standard of care for age-related diseases.
See full Gero company page
